Skip to main content
Premium Trial:

Request an Annual Quote

Accelr8 Posted Flat Q3 Revenue as R&D Spend Was Cut in Half and Losses Narrowed 40 Percent

NEW YORK (GenomeWeb News) — Accelr8 last week reported that third-quarter revenues were stable while R&D spending fell by half and losses narrowed 40 percent.
Total receipts for the three months ended April 30 increased to $22,700 from $19,800 year over year.
The company’s only revenue came from its OptiChem product line.
R&D spending was slashed to $247,500 from $490,000 year over year.
The company said net losses decreased to $477,000 from $789,000 in the year-ago period.
"The reduced losses reflect our planned transition from a product-engineering phase to an intensive testing phase using laboratory prototypes,” Accelr8 president David Howson said in a statement.
The company is testing an assay for methicillin-resistant Staphylococcus aureus infections, which are common in hospitals and be fatal.
Accelr8 said it had around $1.8 million in cash and cash equivalents as of April 30.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more